Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2239a823a5eb6ed

Jump to content

// Workers AI · dad joke modeWhy did Hycor go to the party? It was a cell-ebration.

From Wikipedia, the free encyclopedia
HYCOR Biomedical
TypeHeadquarters
IndustryAllergy Testing Diagnostics
Founded1981
Headquarters
Area served
Worldwide
Websitehttps://www.hycorbiomedical.com/

HYCOR Biomedical is an American corporation specializing in the manufacture and supply of in vitro diagnostic products for blood testing for allergies. The company is headquartered in Garden Grove, California, with offices in Amsterdam, Netherlands.

The company was acquired by Linden Capital Partners in early 2010.[1]

History

[edit]

HYCOR Biomedical was founded by Steve Gorlin in 1981 in Garden Grove, California.[2]

Products and services

[edit]

The fully-automated NOVEOS Immunoanalyzer uses only 4 microliters of sample per test, paramagnetic microparticles as a solid phase, chemiluminescence and fluorescence methodology for high sensitivity, and liquid ready-to-use reagents.

The HYTEC 288 Plus EIA system continues to serve laboratories around the world. The NOVEOS system helps reduce interference issues and the amount of a sample needed to perform testing.

Currently[when?], HYCOR Biomedical has an estimated 5% market share[3] in allergy testing.

Allergy testing

[edit]

The more common method for allergy testing, called skin prick testing, relies on examining a patient's reaction to the exposed allergen,[4] and in some cases, invokes large systemic reactions.[5] With a growing need for testing younger patients[6] without putting them at risk, in vitro testing has become an increasingly more viable alternative.

References

[edit]
  1. "Linden Acquires Hycor Biomedical Business from Agilent Technologies". www.investor.agilent.com. Retrieved 2026-05-20.
  2. "HYCOR Biomedical Raises $20M to Expand Allergy Testing - dot.LA". dot.la. Retrieved 2026-06-29.
  3. "College of American Pathologists - Allergy testing: from skin to tube to chip". www.cap.org. Archived from the original on 2018-02-27. Retrieved 2026-06-11.
  4. "Find the Source of Allergies". WebMD.
  5. Liccardi, G.; D'Amato, G.; Canonica, G. Walter; Salzillo, A.; Piccolo, A.; Passalacqua, G. (2006). "Systemic reactions from skin testing: literature review". Journal of Investigational Allergology & Clinical Immunology. 16 (2): 75–78. ISSN 1018-9068. PMID 16689179.
  6. Burks, Wesley (April 1, 2003). "Peanut allergy: a growing phenomenon". The Journal of Clinical Investigation. 111 (7): 950–952. doi:10.1172/JCI18233. PMC 152593. PMID 12671042.